This assay can be used
- To aid in the management of patients suffering from malignant melanoma (Elecsys S100 assay is not suitablefor the diagnosis of malignant melanoma).
- To aid in the management of patients after potential brain injury in conjunction with clinical information and imaging techniques
ECL (ElectroChemiLuminescence) is Roche’s technology for immunoassay detection. Based on this technology and combined with well-designed, specific and sensitive immunoassays, Elecsys delivers reliable results. The development of ECL immunoassay is based on the use of a ruthenium-complex and tripropylamine (TPA).
The chemiluminescence reaction for the detection of the reaction complex is initiated by applying a voltage to the sample solution, resulting in a precisely controlled reaction. ECL technology can accommodate many immunoassay principles while providing excellent performance.